Light-Activated Copper Complex Kills Treatment-Resistant Cancer Cells One Hundred Times More Effectively Than Traditional Chemotherapy

Ruhr University Bochum researchers unveil a light-activated copper complex that kills resistant cancer cells 100x more effectively via cuproptosis.

By: AXL Media

Published: Mar 26, 2026, 8:42 AM EDT

Source: Information for this report was sourced from Ruhr-Universitaet-Bochum

A New Frontier in Targeted Cellular Destruction

The discovery of cuproptosis in 2022 has provided a novel pathway for oncology research, centering on a previously unknown form of cell death triggered by copper overload. Professor Johannes Karges and his team at Ruhr University Bochum have leveraged this biological vulnerability to create a copper-based agent complex that demonstrates remarkable potency. According to the research published in Advanced Functional Materials, this new complex is approximately 100 times more effective at killing cells than the platinum derivatives currently utilized in clinical settings. This breakthrough suggests a major shift in how researchers approach the destruction of malignant tissue.

Disrupting the Metabolic Engine of Malignancy

The mechanism of cuproptosis is fundamentally distinct from other forms of cell death because it targets the mitochondria, the energy-producing centers of the cell. When an excess of copper is introduced, it binds to specific mitochondrial proteins, causing them to clump together and induce extreme cellular stress. According to Professor Karges, cancer cells are particularly susceptible to this process because they often possess an altered and intense metabolism. This metabolic profile causes them to absorb significantly more copper than healthy tissue, effectively turning their own growth requirements into a fatal weakness.

Nanoparticle Packaging for Precision Delivery

To overcome the initial challenge of the copper complex being toxic to healthy cells, the research team engineered a sophisticated delivery system using polymeric nanoparticles. These particles are designed to accumulate selectively within tumor tissue, taking advantage of the increased metabolic activity of the cancer. This packaging serves a dual purpose: it ensures the agent reaches its intended destination while preventing the copper complex from being released prematurely into the bloodstream. This containment strategy is essential for minimizing the systemic side effects typically associated with high-potency chemotherapy.